Navigation Links
Erika Schwartz MD Congratulates Oprah Winfrey for Spotlighting Bioidentical Hormones
Date:1/15/2009

For now, she says: "Let's just celebrate the fact that bioidentical hormones are coming out and are finally being considered as viable treatments for feeling lousy. No longer are we hearing that bioidenticals are just a marketing term. Now that is progress!

New York, NY (PRWEB) January 15, 2009 -- Today is a big day for women's health and bioidentical hormones, says Erika Schwartz MD in her latest blog at www.derika.com.

For the first time, she says, mainstream media is acknowledging that women are suffering unnecessarily and that hormone imbalance is an overwhelming handicap that needs attention and legitimate treatments. It can no longer be swept under the rug.

Dr. Erika notes it took someone like Oprah Winfrey, who is suffering from inadequately treated thyroid problems, menopausal hormone loss and its attendant weight gain to blast the hinges off the door to bioidentical hormone therapy.

Acknowledgement is always the precursor to enlightenment, she adds.

Dr. Erika says she hopes Oprah will consider bioidenticals an important ingredient in her commitment to achieving true wellness.

For now, she says: "Let's just celebrate the fact that bioidentical hormones are coming out and are finally being considered as viable treatments for feeling lousy. No longer are we hearing that bioidenticals are just a marketing term. Now that is progress!

"The next step involves educating the medical community about the existence of bioidenticals, providing them with the studies about them, teaching them the difference between how bioidenticals and non-identical hormone molecules work in the human body and making sure they know that bioidenticals are FDA approved and available at your local drugstore."

Dr. Erika says doctors also need to understand the role and usefulness of compounding pharmacies and get involved with who compounds the hormones they prescribe.

Finally, Dr. Erika says, balanced and honest studies must be undertaken on a large scale and in full view that compare the efficacy and safety of bioidenticals to their non-identical counterparts. The era of creating confusion and muddying the waters of hormone therapies has reached its end.

DrErika.com is dedicated to providing an independent, honest view on healthcare topics and issues from a position of devoted patient advocacy.

Its founder, Erika Schwartz MD, is an internationally-recognized patient advocate, practicing physician, expert in conventional and integrative medicine, author of four books and a frequent guest on TV and radio. DrErika.com doesn't tailor its stories to suit sponsors - it does not accept sponsors.

# # #

Read the full story at http://www.prweb.com/releases/2009/01/prweb1872574.htm


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
2. Steve and Paula Mae Schwartz Honored With Publicity Club of New Englands Crystal Bell Award
3. SAND Technology Appoints Zainab Ahmed Schwartz as CFO
4. The Kenneth B. Schwartz Center, ASTRO partner to raise awareness of cancer survivorship
5. Anapol Schwartz Attorney Named to Executive Committee of American Association for Justice
6. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
7. American Heart Association Congratulates Pioneer Heart Surgeon for Being Named Recipient of Congressional Gold Medal Award
8. Mission Pharmacal Congratulates Exemplary Womens Health Researchers
9. Internet2 Congratulates FCC Rural Health Care Pilot Program Grant Awardees
10. SNM congratulates NOPR and its supporting organizations on successful conclusion of project
11. Coalition for 21st Century Medicine Congratulates U.S. Senate on Passage of Genetic Information Nondiscrimination Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... have severe consequences to overall dental health, including complications with speech, eating, and overcompensation ... dental implants to replace lost teeth. As the number of tooth replacements increase, it ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Hackensack, N.J. has been honored by Enterprising Women magazine as one of its ... world’s top women business owners. Winners have demonstrated that they have fast-growth businesses, ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 Solentim, the ... announced the addition of a major new product ... Plate Seeding,). The VIPS has been developed for ... well microplates as part of the process to ... a simple and more reliable solution when compared ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: